3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Genitourinary
1
CNS
1
Conditions
Sarcoma
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
8
pembrolizumab
6
Filgrastim
5
Busulfan
5
fludarabine phosphate
4
fludarabine
4
Nivolumab
4
Flow Cytometry
4
Antilymphocyte Serum
4
Alemtuzumab
4
Tacrolimus
3
Stem Cell Transplantation
3
Sirolimus
3
Radiotherapy
3
Peripheral Blood Stem Cell Transplantation
3
Paclitaxel
3
Mycophenolic Acid
3
Melphalan
3
Dexamethasone
3
Carboplatin
3
Biopsy
3
Azacitidine
3
valspodar
2
atezolizumab
2
aldesleukin
2
X-Rays
2
Vorinostat
2
Vincristine
2
Thiotepa
2
Psychiatric Rehabilitation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
CLR1404
×
Genitourinary
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled